Teva Pharmaceutical Industries Limited American Depositary Shares

Teva and the FDA seem to have differing views on what is causing the shortage.

Teva Pharmaceuticals reportedly recalls more than 2.5 million vials of drugs due to potential contamination.

Endo said the settlement includes no admission of wrongdoing by Endo or its subsidiaries.

Tilray, Boeing, Alphabet, QuantumScape and Teva Pharmaceutical are five top stock gainers for Wednesday.

Teva maintains its earnings guidance for the year.

Teva Pharmaceutical reportedly stopped looking for partners to develop a COVID vaccine, saying candidates went with other companies.

Teva's fourth-quarter adjusted earnings top analysts' forecasts. Revenue falls from a year earlier but also beats forecasts.

Teva shares were lower after the drugmaker's adjusted earnings matched analyst expectations while revenue lagged.

For some stocks, earnings are essential. But Jim Cramer has a 'Magnificent Seven' list of growth stocks for which it seems like every day is a buying opportunity.

Johnson & Johnson Faces New York State Insurance Fraud Action Linked to Opioid Crisis

Teva may face a federal charge stemming from a price-fixing investigation, a media report says.

The government claims that kickbacks Teva paid for its multiple sclerosis drug Copaxone led to false Medicare claims.

Berkshire Hathaway revenue expected to fall 4% to $61.1 billion.

Mylan, Teva, Taro and Perrigo are among those accused of price-fixing, market allocation and bid-rigging on 80 topical drugs.

Jim Cramer says there are good reasons for this reopening rally, and support from the Fed and Treasury. But job losses are a worry.

Latest SEC filings also show Berkshire Hathaway added to PNC holdings.

Teva reports rising demand for its respiratory drugs amid the Covid-19 pandemic.

Here is TheStreet's latest news on the coronavirus and its worldwide and economic impact, and a timeline of events since January

Teva plans to give those shipments to U.S. hospitals by March 31 and another 4 million within a month.

Here are some cheap names I'm playing via covered-call orders.

Let's check and see how my trade is going.

Let's get a technical take on the health of the pharma play.

The stock has been in an impressive uptrend over the past 12 months. Now, let's let the charts determine our trading strategy from here.

This options strategy is prudent while the company navigates through an inflection point.

Let's check the inverse move today in which the indexes got hit and breadth held fast, also let's check the banks and the biotechs.

These small and mid-cap names have seen major news of late.

The TLT is holding onto that $100 area for dear life, and here's what breaking it could mean -- and why this is so fascinating.

The shares rallied nicely in December.

For those who thought the indicators would resolve to get it together in the new year and end this weeks' long on-and-off chop, think again. Also, let's look at new lows on the Nasdaq since August and the oversold/overbought condition.

Let's see where we haven't gone in a month -- also let's check the buck, small caps and the intermediate-term indicators.

Let's check the charts of this generic drug maker.

Antares Pharma showed solid earnings in the fourth quarter. Here's our take.

Breaking down first-quarter reports from Energy Recovery, Antares Pharma and 22nd Century Group.

Let's review the charts and indicators.

An update on Antares Pharma and where we stand with our price target.

Results for Antares Pharma were driven by Xyosted, the company’s hottest product.

Antares Pharma had a better quarter than expected, so let's look at the company in detail here.

Statistically speaking, it was, how shall we say this, bad.

The retail goliath has more plans for its brick-and-mortar operations.

The retailer is making a swift change to a previously lenient policy.

Netflix announces major price hikes in its membership tiers and its shares skyrocket.